David Wiltfong, MD
Urology · Lincoln, NENPI 1467475731
Payments from drug & device makers
Across 322 payments — averaging $39.34 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Angiodynamics, Inc.$6K
- Procept Biorobotics Corporation$836
- Johnson & Johnson$634
- Sumitomo Pharma America, Inc.$634
- Astellas Pharma US Inc$623
- AbbVie$455
- plus $4K from 42 others
What the payments were for
- Consulting fees$1001%
- Travel & lodging$2562%
- Food & beverage$6,24449%
- Education$4273%
- Other$5,63945%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Nanoknife$5,639
- AQUABEAM SYSTEM$561
- Brachytherapy Source$330
- UroLift$136
- GENERAL ERECTILE DYSFUNCTION$134
- JELMYTO$125
- KEYTRUDA$100
How this compares
$12,667 in reported general payments places this provider in the 70th percentile of 79 urology providers in Nebraska.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XtandiEnzalutamide | 21 | $283,481 |
| MyrbetriqMirabegron | 63 | $31,503 |
| GemtesaVibegron | 15 | $7,905 |
| Tamsulosin Hcl | 91 | $1,198 |
| Bethanechol Chloride | 18 | $483 |
| Solifenacin Succinate | 18 | $412 |
| Finasteride | 58 | $397 |
| Ciprofloxacin Hcl | 105 | $288 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 74 | $204 |
| Oxybutynin Chloride ErOxybutynin Chloride | 12 | $109 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Astellas Pharma US IncXtandi, Myrbetriq | $623 | $314,98384 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $634 | $7,90515 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 79 urology providers in Nebraska.
Other urology in Lincoln
- Lance WiebuschLincoln$63K
- Antonio BeltranLincoln$51K
- Sushil LacyLincoln$20K
- Thomas BrushLincoln$15K
- Adam MuesLincoln$14K
- Logan McGuffeyLincoln$10K
- Aaron PomajzlLincoln$9K
- Tara KirkpatrickLincoln$8K
- Brandon HensleeLincoln$7K
- Andrew LepinskiLincoln$4K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.